Thomas Graves
Family · Newark, DENPI 1942729819
Payments from drug & device makers
Across 125 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocryst US Sales Co., LLC$419
- GSK$411
- AstraZeneca$180
- CSL Behring$170
- Novartis$153
- Pfizer$129
- plus $691 from 19 others
What the payments were for
- Food & beverage$2,07196%
- Education$814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocryst US Sales Co., LLC | 19 | $419 |
| GSK | 30 | $411 |
| AstraZeneca | 9 | $180 |
| CSL Behring | 10 | $170 |
| Novartis | 9 | $153 |
| Pfizer | 9 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $117 |
| Sanofi | 6 | $96 |
| AbbVie | 3 | $73 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Regeneron Healthcare Solutions, Inc. | 3 | $60 |
| Boehringer Ingelheim | 2 | $34 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $32 |
| Genentech USA, Inc. | 1 | $24 |
| Grifols USA, LLC | 1 | $22 |
| Aerin Medical Inc. | 1 | $21 |
| LEO Pharma Inc. | 1 | $20 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Kaleo, Inc. | 1 | $16 |
| Alk-abello, Inc | 1 | $16 |
| Optinose US, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$2,151 in reported general payments places this provider in the 80th percentile of 523 family providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 40 | $254,209 |
| Dupixent SyringeDupilumab | 18 | $93,852 |
| Dupixent PenDupilumab | 22 | $90,704 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $52,366 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $51,363 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $39,372 |
| XolairOmalizumab | 12 | $32,704 |
| Arnuity ElliptaFluticasone Furoate | 14 | $9,141 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $7,885 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 45 | $6,053 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $3,170 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 70 | $2,698 |
| Montelukast Sodium | 146 | $2,297 |
| Azelastine Hcl | 65 | $2,193 |
| Epinephrine | 12 | $2,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $170 | $254,20940 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $411 | $100,880111 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $180 | $59,24867 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 523 family providers in Delaware.
Other family in Newark
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Melanie HiesterNewark$9K
- Samatha GrayNewark$9K
- Byron MayNewark$8K
- Clare MatisNewark$8K
- Christine MazzolaNewark$7K
- Kelsey FrybergerNewark$7K
- Colleen AllenNewark$7K
- Mallory KowalskiNewark$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.